<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kwality Pharmaceuticals Limited has submitted a confirmation to BSE stating that it is not identified as a Large Corporate (LC) as of March 31, 2026. This confirmation is in compliance with SEBI Circular SEBI/HO/DDHS/DDHSPOD1/P/CIR/2023/172 dated October 19, 2023, which pertains to fund raising by issuance of debt securities by large entities. The company, listed on BSE with Scrip Code 539997, is clarifying that it does not meet the applicability criteria for Large Corporate classification. The filing was signed by Gurpreet Kaur, Company Secretary & Compliance Officer, dated April 30, 2026.
This is a routine regulatory compliance filing with no direct impact on shareholders or stock price. The company is simply confirming its non-classification as a Large Corporate, which means it is not subject to the enhanced disclosure and compliance requirements applicable to larger entities under SEBI guidelines.